Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some Long Islanders and are numbered for others, pharmacists and compounding industry groups say.

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...

Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame’s direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...

Mounjaro and Zepbound are Eli Lilly's largest sources ... to treat chronic weight management and diabetes. While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another ...